Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab vs platinum-based chemotherapy in first-line PD-L1-high advanced NSCLC
2018-001375-21Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Durvalumab monotherapy with Standard-of-care platinum-based chemotherapy (2 arms). Primary endpoint: overall survival. Started May 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001375-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001375-21.